Neither study can definitively describe the optimal order of biologic therapy use, although the 2017 meta-analysis by Arnold and colleagues [20] suggested that the best therapeutic strategy in patients with wild-type RAS with a left-sided tumor would be to start with a combination of chemotherapy plus anti-EGFR therapy followed by second-line chemotherapy plus an anti-VEGF agent. This evidence concerns the gene EGFR and neoplasm.